Calcium Signaling is Dispensable for Receptor-Regulation of Endothelial Barrier Function

Judith A. Stolwijk1,3, Xuexin Zhang1, Maxime Gueguinou1, Wei Zhang1, Khalid Matrougui2, Christian Renken3, and Mohamed Trebak1,4

1From Department of Cellular and Molecular Physiology, Penn State University College of Medicine; 2Department of Physiological Sciences, East Virginia Medical School, Norfolk, VA; and 3Applied Biophysics Inc., Troy NY

Running Title: Calcium signaling and endothelial barrier function

4Correspondence to: Mohamed Trebak, PhD. Department of Cellular and Molecular Physiology, Penn State University College of Medicine, 500 University Dr. Hershey PA 17033, Phone: (717) 531-8152, email: mtrebak@hmc.psu.edu

Keywords: Endothelial barrier function, Calcium signaling, GPCR signaling, Orai1, STIM1

ABSTRACT

Endothelial barrier function is tightly regulated by plasma membrane receptors and is crucial for tissue fluid homeostasis; its dysfunction causes disease, including sepsis and inflammation. The ubiquitous activation of Ca\(^{2+}\) signaling upon phospholipase C (PLC)-coupled receptor ligation leads quite naturally to the assumption that Ca\(^{2+}\) signaling is required for receptor-regulated endothelial barrier function. This widespread hypothesis draws analogy from smooth muscle and proposes the requirement of G protein coupled receptor (GPCR)-generated Ca\(^{2+}\) signaling in activating the endothelial contractile apparatus and generating inter-endothelial gaps. Notwithstanding endothelia being non-excitable in nature, the hypothesis of “Ca\(^{2+}\)-induced endothelial contraction” has been invoked to explain actions of GPCR agonists that either disrupt or stabilize endothelial barrier function. Here, we challenge this correlative hypothesis by showing lack of causal link between GPCR-generated Ca\(^{2+}\) signaling and changes in human microvascular endothelial barrier function. We used three endogenous GPCR agonists; thrombin and histamine which disrupt endothelial barrier function; and Sphingosine-1-phosphate (S1P) which stabilizes barrier function. The qualitatively different effects of these three agonists on endothelial barrier function occur independently of Ca\(^{2+}\) entry through the ubiquitous store-operated Ca\(^{2+}\) entry (SOCE) channel Orai1, global Ca\(^{2+}\) entry across the plasma membrane and Ca\(^{2+}\) release from internal stores. However, disruption of endothelial barrier function by thrombin and histamine requires the Ca\(^{2+}\) sensor STIM1, while S1P-mediated enhancement of endothelial barrier function occurs independently of STIM1. We conclude that while STIM1 is required for GPCR-mediated disruption of barrier function, a causal link between GPCR-induced cytoplasmic Ca\(^{2+}\) increases and acute changes in barrier function is missing. Thus, the “cytosolic Ca\(^{2+}\)-induced endothelial contraction” is a cum hoc fallacy that should be abandoned.

INTRODUCTION

The endothelial layer of blood vessels is a highly regulated barrier between the bloodstream and the interstitial tissue, controlling trans-vascular passage of fluids, solutes and cells. A significant contribution to endothelial permeability resides in the paracellular diffusion pathway facilitated via intercellular gaps (1-3). Paracellular
Calcium signaling and barrier function

Permeability is essentially mediated by cell-cell junctional proteins, which are in turn regulated by intracellular signaling pathways that impact on cytoskeletal architecture (2,4). The balance between competing tethering and disassembling mechanisms determines the degree of endothelial barrier function and thus the extent of vascular leakage. Disruption of endothelial barrier function causes increased vascular permeability and is associated with reorganization of the actin cytoskeleton and disassembly of adherens junctions which are contributed by vascular endothelial cadherin (VE-cadherin)/catenin complexes (2,4). These events are under the control of various signaling pathways, which are activated by diverse paracrine and autocrine mediators in blood and interstitial tissue, many of which act on heterotrimeric G protein-coupled receptors (GPCR) or receptor tyrosine kinase and play crucial roles in the control of vascular permeability, tone, angiogenesis and inflammation (2-4).

Barrier disrupting GPCR agonists including thrombin and histamine activate downstream signaling that regulate actin reorganization and VE-cadherin localization triggered by activation of the small GTPase RhoA (1,2). GPCR-mediated activation of the heterotrimeric G-protein Ga12/13 family subtype causes the association and activation of p115Rho guanine nucleotide exchange factor (p115RhoAGEF), leading to RhoA activation (1,2). RhoA then activates Rho kinase (ROCK) which phosphorylates the regulatory subunit of the myosin light chain phosphatase (MLCP) and inhibits its activity. This in turn enhances the phosphorylation of MLC causing actin-myosin interactions and disruption of endothelial barrier function (5). Furthermore, ROCK can directly phosphorylate MLC to cause barrier disruption (6). The signaling pathways activated downstream barrier-stabilizing GPCR agonists such as the Sphingosine-1-Phosphohate (S1P) are less understood. S1P acts on heteromultimeric Ga1 proteins leading to the activation of the small GTPase Rac and focal adhesion kinase (FAK), thus promoting formation of focal adhesions, cortical actin and adherens junction assembly (3,7).

While it is obvious that endothelial cells develop force in response to barrier-disrupting agonists such as thrombin and histamine, the tension developed by endothelial cells in response to the most powerful agonist thrombin is at least 50 fold weaker than the bona fide tension generated by smooth muscle cells during contraction (8). Nevertheless, during the past three decades Ca2+-dependent endothelial contraction - a concept extrapolated from studies on muscle cells - has been invoked to explain changes in endothelial barrier function downstream GPCR agonists. Barrier disrupting GPCR agonists such as thrombin and histamine activate Ga11 protein and induce the production of inositol-1,4,5-trisphosphate (IP3) through the action of phospholipase C (PLC). This will result in Ca2+ release from the IP3-sensitive internal stores of the endoplasmic reticulum (ER) and activation of Ca2+ entry across the plasma membrane (PM) through the ubiquitous store-operated Ca2+ entry (SOCE) pathway activated by ER store depletion (9). It is now appreciated that ER store depletion causes the ER-resident Ca2+ sensor stromal-interacting molecule 1 (STIM1) to move towards ER-PM junctional spaces to trap and directly activate Orai1 Ca2+ entry channels (10-17). According to the Ca2+-dependent model, the sustained Ca2+ entry signal thus generated (but not Ca2+ release) activates a key Ca2+- and calmodulin-dependent kinase, the myosin light chain kinase (MLCK) leading to MLC phosphorylation, formation of actin stress fibers and endothelial contraction resulting in formation of inter-cellular gaps (3,18-21). For the barrier-stabilizing agonist S1P, Ca2+ release from internal stores, but not Ca2+ entry, was proposed to induce Rac activation.
thus promoting assembly of adherens junctions and strengthening of endothelial barrier function (22).

Early studies from our group and others demonstrated that in endothelial cells from various vascular beds (human pulmonary artery, human dermal microvasculature, human umbilical vein) thrombin, vascular endothelial growth factor (VEGF) and the store-depleting drug thapsigargin activate SOCE encoded by STIM1 and Orai1 (11, 23-25). In a recent study, we have challenged the hypothesis that SOCE is required for endothelial contraction in response to the powerful barrier-disrupting agonist thrombin (23). We demonstrated using molecular tools that thrombin-mediated endothelial barrier disruption required the ER-resident STIM1 protein, but occur independently of SOCE, Orai1 and MLCK (23). We also showed that STIM1 is required for RhoA activation, MLC phosphorylation, actin reorganization and disruption of intercellular adhesions (23).

In the current study, we set out to determine whether these findings are unique to thrombin or shared by other barrier-altering or barrier-enhancing GPCR agonists; and whether Ca\(^{2+}\) release from the ER is required for agonist-mediated effects on endothelial barrier function. We thus used high throughput impedance measurements to determine the role of Ca\(^{2+}\) release and Ca\(^{2+}\) entry mechanisms in regulating endothelial barrier function downstream of three GPCR agonists, namely thrombin, histamine and S1P. Thrombin and histamine are two typical inflammatory agonists which cause transient barrier disruption while the platelet-derived agonist S1P enhances endothelial barrier function. These three agonists are of major relevance to vascular pathologies such as inflammation, allergy and atherosclerosis. We compared side by side the effects of these three agonists on endothelial barrier function using electrical measurements and fluorescence microscopy. We also monitored the Ca\(^{2+}\) release from stores and Ca\(^{2+}\) entry across the plasma membrane induced by these agonists. We report that while Ca\(^{2+}\) signaling in response to these agonists coincides with changes in barrier function, neither Ca\(^{2+}\) entry nor Ca\(^{2+}\) release are necessary for GPCR-mediated disruption or enhancement of barrier function. We show that Orai1 plays no significant role in thrombin-, histamine-, and S1P-induced changes in endothelial barrier function. However, STIM1 is required for disruption of endothelial barrier function by thrombin and histamine but is not involved in S1P-mediated enhancement of endothelial barrier function.

RESULTS

Thrombin, histamine and S1P evoke distinct impedance response profiles in HDMECs-

Impedance measurements were performed in monolayers of human dermal microvascular endothelial cells (HDMEC) before and after addition of GPCR agonists using ECIS protocols as described in methods and outlined in details recently (26). Upon stimulation of confluent HDMEC monolayers with GPCR agonists, thrombin, histamine and S1P, each agonist showed a typical response as shown in Fig. 1. While thrombin and histamine lead to a transient disruption of endothelial barrier function (Fig. 1A, B), S1P enhanced (or stabilized) endothelial barrier function (Fig. 1C). Furthermore, the barrier-disrupting response of HDMEC monolayers to thrombin and histamine differed in severity and kinetics; thrombin effects were more profound and barrier took over an hour to recover while histamine effects were modest in comparison and recovery of the barrier to pre-agonist levels occurred within 10 minutes (Fig. 1A, B). Changes in electrical resistance on ECIS electrodes are caused by changes in cell morphology and changes at the
Calcium signaling and barrier function

intercellular junctions caused by rearrangements of actin and adherens junction proteins. The opening of cell-cell junctions increases paracellular current flow, and thus, causes decreases in resistance. Reciprocally, strengthening of cell-cell junctions reduces paths for current flow and leads to resistance increases. These results are consistent with cell morphology changes that were assessed microscopically: Immunofluorescence staining for actin (green) and VE-cadherin (red) under control conditions and 2 min after addition of the respective agonists showed that while thrombin caused a disruption of adherens junctions, spanning the full length of cell-cell contact sites, histamine caused localized small oval-shaped openings that seem lacking VE-cadherin staining (Fig. 1D). S1P on the other hand led to increased VE-cadherin staining at the cell-cell junctions (Fig. 1D). To illustrate the changes in VE-cadherin and actin distribution during the time course of HDMEC response to thrombin and histamine, cell layers were stained at specific time points after agonist addition as indicated by red arrows in Fig. 1E for thrombin and Fig. 1F for histamine. HDMEC immunofluorescence images representing time points at 2, 5, 10 and 30 min after thrombin stimulation and 1, 5 and 20 min after histamine stimulation are shown in Fig. 1G and 1H, respectively. For comparison, typical control non-stimulated HDMEC monolayers are shown in Fig. 1I. According to the Ca\textsuperscript{2+}-induced contractility model, tension produced through actin stress fiber formation upon agonist stimulation of endothelial cells is required for barrier disruption (3). The fluorescence micrographs show that within the first 2 – 5 minutes after thrombin stimulation actin redistributes into the cytosol away from cell-cell contacts, which also leaves a staining pattern of interrupted VE-cadherin/actin co-localization (yellow) at the cell borders (Fig. 1G). Increased proportion of distinct actin bundles became visible after 10 min of thrombin stimulation, during the monolayer recovery phase (Fig. 1G). Additional quantification of fluorescence intensity from actin and VE-cadherin across cell cross-sections reveals actin accumulation in central regions of the cell at 2 – 10 min after thrombin stimulation, whereas in untreated and S1P-stimulated cell layers actin is predominantly co-localized with VE-cadherin at the cell borders, as indicated by overlap of intensity peaks (Fig. 1J). After 30 min of thrombin stimulation, at which time HDMEC monolayer resistance was typically restored by ~80% of basal levels (Fig. 1E), accumulation of actin toward the cell borders was evident (Fig. 1G, J). Similarly, in HDMEC monolayers stimulated with histamine, the appearance of stress fibers occurred 20 min after agonist stimulation (Fig. 1H), but was clearly absent in early stages, where decrease in resistance was maximal (Fig. 1F) and fluorescence intensity of actin and VE-cadherin staining decreased at the cell borders (Fig. 1J). These data suggested to us that the rapid decrease in barrier function in response to thrombin and histamine precedes stress fiber formation. Initial breakdown of endothelial barrier might be rather due to redistribution of actin away from the cell-cell junctional sites, thereby weakening junctional complexes. In turn, actual actin fiber formation might be more important during the barrier recovery phase when actin redistributes back toward the cell junctions for their stabilization. Thus, actin stress fiber tension might not be necessary for GPCR-mediated barrier breakdown.

Thrombin, histamine and S1P activate SOCE in HDMECs-

We tested if Ca\textsuperscript{2+} signaling is activated in HDMECs by our three model agonists and if Orai1 and STIM1 mediate store-operated Ca\textsuperscript{2+} entry (SOCE) in response to these agonists as was shown for virtually all cell types, including endothelial cells (10,11,13,27,28). We and others have shown that GPCR and
Calcium signaling and barrier function

receptor tyrosine kinase agonists activated Ca\textsuperscript{2+} entry into endothelial cells (from various vascular beds including HDMEC) through SOCE bearing typical pharmacological signature and mediated by Orai1 and STIM1 (11,12,23,24). Like thrombin, the other two GPCR agonists considered under this study (histamine and S1P) also couple to PLC activation with generation of IP\textsubscript{3}, activation of Ca\textsuperscript{2+} release from internal stores and subsequent activation of Ca\textsuperscript{2+} entry across the plasma membrane presumably through the SOCE pathway. One of the most common means to activate SOCE without stimulating membrane receptors and without generating second messengers is to passively deplete the internal Ca\textsuperscript{2+} stores using the Sarcoplasmic/Endoplasmic Reticulum Ca\textsuperscript{2+} ATPase (SERCA) inhibitor thapsigargin (29). Treatment of HDMEC with thapsigargin in the absence of extracellular Ca\textsuperscript{2+} led to a typical transient response corresponding to Ca\textsuperscript{2+} release from internal stores (Fig. 2A, black trace). Restoration of 2 mM Ca\textsuperscript{2+} to the external buffer revealed a second response corresponding to Ca\textsuperscript{2+} entry across the plasma membrane (Fig. 2A, black trace). These typical Ca\textsuperscript{2+} release and Ca\textsuperscript{2+} entry profiles can be readily observed when HDMEC are stimulated with thrombin, histamine or S1P under the same recording protocol (Fig. 2B–D, black traces). Note that while 5 nM thrombin induces maximal changes in endothelial barrier function (Fig. 1A), concentrations of 100 nM thrombin were required to obtain significant Ca\textsuperscript{2+} responses to thrombin.

To show involvement of SOCE upon GPCR activation, as a first step, we systematically tested side by side the effect of different commonly used SOCE inhibitors on the HDMEC response to thapsigargin and the three GPCR agonists, thrombin, histamine and S1P (Fig. 2). We used three different SOCE channel inhibitors, the lanthanide ion Gd\textsuperscript{3+} at relatively low concentrations of 5 µM is a specific inhibitor of SOCE (30,31), BTP2 (32-35) and 2-APB (36,37). Ca\textsuperscript{2+} entry (but not Ca\textsuperscript{2+} release) in response to thapsigargin and all three agonists was inhibited by 5 µM Gd\textsuperscript{3+} (Fig. 2A–D; red traces) 10 µM BTP2 (Fig. 2E–H, red traces) and 25 µM 2-APB (Fig. 2I–L). As shown in Figure 2, these commonly used SOCE inhibitors inhibited the Ca\textsuperscript{2+} entry phase when cells were either treated with drugs 2 minutes before addition of agonist (red traces) or when drugs were added after Ca\textsuperscript{2+} entry has developed (control black traces, arrow indicates addition of drug). Specifically, Ca\textsuperscript{2+} entry in response to thapsigargin, thrombin and histamine was potentiated by 2-APB at 5 µM and inhibited at 25 µM (Fig. 2I–K; black traces), a defining peculiarity of Orai1-mediated SOCE (36,38). Furthermore, when cells were pre-incubated with 5 µM 2-APB before addition of thapsigargin, thrombin or histamine (Fig. 2I–K; blue traces), the Ca\textsuperscript{2+} entry phase was enhanced but when 25 µM 2-APB was subsequently added, Ca\textsuperscript{2+} entry was inhibited.

In conclusion, all three model GPCR-agonists thrombin, histamine and S1P can activate Orai1-mediated SOCE in HDMEC in a manner reminiscent of passive store depletion with thapsigargin.

Effect of SOCE inhibitors on GPCR-mediated endothelial barrier regulation-

We previously showed that blockade of SOCE in HDMEC with 5 µM Gd\textsuperscript{3+} did not affect thrombin-mediated disruption of barrier function (23). This original finding led to the hypothesis that Ca\textsuperscript{2+} entry is not necessary for mediating typical acute barrier responses to GPCR agonists. Therefore, we decided here to systematically test the effects of all three SOCE inhibitors (Gd\textsuperscript{3+}, 2-APB and BTP2) on the barrier-modulating effects of the three GPCR agonists, thrombin (5 nM), histamine (10 µM) and S1P (1 µM) by using impedance measurements. HDMEC cell layers grown onto ECIS electrodes were subjected to the
three SOCE inhibitors, Gd\(^{3+}\), BTP2 and 2-APB. Dose response curves showed that when these inhibitors were added to HDMEC monolayers, without additional GPCR stimulation, they significantly altered the baseline resistance of the monolayers at higher concentrations, 25 µM for Gd\(^{3+}\), 5 µM for BTP2 and 25 µM for 2-APB (Fig. 3A – C). BTP2 effects were transient with a recovery to baseline values within 2 – 3 hours (Fig. 3B). Because of these intrinsic inhibitor effects, in all subsequent data related to effects of inhibitors on GPCR-mediated changes in barrier function, for the sake of transparency, we thought it more appropriate to represent raw traces that are not background subtracted (i.e. without subtracting from these data resistance values obtained with inhibitors alone).

The addition of 5 µM Gd\(^{3+}\) to HDMEC monolayers, which fully blocked SOCE without affecting the basal monolayer resistance, did not affect the typical changes in cell layer resistance upon stimulation with thrombin, histamine or S1P (Fig. 4A – C). All traces from Fig. 4 represent averages from 3 – 4 wells per condition from a single HDMEC isolation. Even higher concentrations of Gd\(^{3+}\) (10 – 50 µM) were without effect on changes in barrier function induced by all three GPCR agonists (Fig. 4A – C). Statistical analysis on maximum change in normalized resistance (Δ Normalized Resistance) in absence or presence of Gd\(^{3+}\) at concentrations of 5, 10 or 50 µM from several independent experiments (4 – 12) involving independent HDMEC isolations showed no statistical significance for all agonists (Fig. 4D – F).

The decrease in monolayer resistance in response to thrombin and histamine was enhanced in the presence of BTP2 (Fig. 5A, B). The transient decrease of resistance observed when BTP2 is added alone (Fig. 3B) is likely responsible for this enhanced decrease in resistance seen when HDMEC monolayers are stimulated with either thrombin or histamine in the presence of BTP2. Indeed, when this effect of BTP2 on basal monolayer resistance is taken into consideration, BTP2 even at higher concentrations that fully inhibit SOCE, has virtually no effect on thrombin- and histamine-mediated disruption of HDMEC barrier function (Fig. 5A, B, Fig. 3B). The lowest concentration of 1 µM BTP2 used in experiments reduced SOCE, without causing full block (data not shown). This was consistent with reported BTP2 effect on Jurkat cells where 1 µM BTP2 resulted in about 25 % inhibition of Orai1-mediated Ca\(^{2+}\) release-activated Ca\(^{2+}\) (CRAC) current (39). With all concentrations of BTP2 used, S1P response profile of HDMEC monolayers was not affected (Fig. 5C). The effect of BTP2 at different concentrations of 1, 5 and 10 µM in experiments (6 – 12) involving HDMEC from several independent isolations is summarized in Fig. 5 D – F.

As discussed in Fig. 3C, 2-APB at 25 µM led to a slow decrease of cell layer resistance over the time course of the measurements and thus seemed to be a side effect of 2-APB, independently of the GPCR agonist used (Fig. 6). Even when taking into consideration this slow effect of 2-APB on basal monolayer resistance (Fig. 3C), treatment of HDMEC on ECIS electrodes with 25 µM 2-APB significantly inhibited the acute and rather fast decrease in resistance after thrombin and histamine stimulation (Fig. 6A, B), but had no significant effect on the S1P-induced increase in monolayer resistance (Fig. 6C). The effect of 2-APB at different concentrations of 5, 10 and 25 µM in experiments (6 – 11) involving HDMEC from several independent isolations is summarized in Fig. 6D – F.

In summary, of the three well-known SOCE inhibitors only 2-APB reliably inhibited the initial fast decrease in HDMEC monolayer resistance induced by thrombin and histamine with marginal effect on S1P-induced
Calcium signaling and barrier function

enhancement of barrier function. Therefore, the effects of 2-APB are clearly not related to inhibition of SOCE and could either be due to non-specific effects of 2-APB on endothelial barrier function or to the ability of 2-APB to block STIM1 oligomerization and re-organization (40), consistent with the reported STIM1-mediated control of barrier dysfunction in response to thrombin that occur independently of Orai1 and Ca\(^{2+}\) entry (23).

To confirm results with SOCE inhibitors we decided to complement these pharmacological data with molecular knockdown in HDMEC monolayers of SOCE components Orai1 and STIM1, as discussed in the following.

Effect of knockdown of Orai1 and STIM1 on GPCR-mediated endothelial Ca\(^{2+}\) signaling and barrier regulation-

For molecular knockdown of Orai1 and STIM1, we used siRNA sequences previously characterized in our laboratory which achieved significant knockdown in 80 – 90% of HDMEC monolayers without off-target effects, specifically on other STIM/Orai isoforms (11,23,41-43). Non-targeting siRNA (siNT) were used as control and knockdown efficiency was quantified by western blot and shown for both STIM1 and Orai1 (Fig. 7A, C) and densitometry results from three (for STIM1) and four (for Orai1) independent transfections were quantified statistically (Fig. 7B, D). Functional evaluation of SOCE activated by passive store depletion using thapsigargin (Fig 7E – H) or agonist stimulation with histamine (Fig. 7I – L) using Fura2 imaging showed significant inhibition of Ca\(^{2+}\) entry after knockdown of either STIM1 or Orai1. The effects of knockdown of STIM1 and Orai1 were quantified from a large number of cells originating from 3 – 4 independent transfections with 6 – 8 independent recordings (Fig. 7F, H, J, L); the two numbers on the bar graphs separated by coma “x, y” represent the number of independent runs (x) and the total number of cells averaged (y). STIM1 and Orai1 knockdown were performed using a second set of sequences (siSTIM1 #2, siOrai1 #2) and effective inhibition of thrombin and histamine-mediated Ca\(^{2+}\) entry was confirmed with these additional sequences (Fig. 7M – T).

Knockdown of either STIM1 or Orai1 had a slight effect on the basal HDMEC monolayer resistance, but this effect was somewhat significant only for Orai1 knockdown (Fig. 8A – D), suggesting a role for Orai1 in proper maturation of HDMEC monolayers. An important observation is that initial baseline values vary significantly depending on the primary cell isolation. The importance of paying attention to initial baseline values and its effect on change in resistance after GPCR activation has been recently discussed in detail (26). A lower initial resistance leads to a smaller resistance change after agonist stimulation, when compared to a cell layer with high initial resistance when all other conditions are equal (26). We quantified the response intensities (ΔR) for each agonist and found a clear dependence of the signal intensity on initial resistance values of the HDMEC cell layers for thrombin and histamine, which was also evident for all types of siRNA used (siNT, siOrai1, siSTIM1) (Pearson’s correlation coefficients 0.58 – 0.87, data not shown). As siRNA treatment itself had no impact on basal HDMEC barrier development after cell seeding compared to siRNA-untreated control HDMEC (Fig. 8E, F), we ascribed differences in baseline unstimulated resistance to variation in cell isolations between human donors. We intentionally chose to conduct knockdown experiments with HDMEC monolayers from different isolations generating different basal resistance values to show general applicability of our findings. Therefore, and as discussed in the next paragraph, ΔR values showed wide variation among different individual experiments.
STIM1 knockdown inhibited the typical decrease in HDMEC monolayer resistance but only upon stimulation with thrombin and histamine with no effect on S1P-induced enhancement of HDMEC monolayer resistance (Fig. 9A – C). However, Orai1 knockdown failed to affect the changes in endothelial barrier function in response to all three GPCR agonists (Fig. 9D – F). Traces in Fig. 9A – F represent averages from N = 4 – 8 per condition from a single HDMEC isolation. To establish solid statistical coverage over different measurements from different cell isolations, statistical analyses were performed on 4 – 10 independent HDMEC isolations for each experimental condition (with 23 – 86 independent wells per condition). Collected data are shown as density plots (Fig. 9G – I). High densities indicate frequent occurrence of respective response intensities (ΔR) and vertical lines represent the mean response intensity. As shown in Fig. 9G and 9H, STIM1 knockdown caused a left-shift in response intensity upon thrombin and histamine stimulation towards lower ΔR values. The respective means of ΔR values from siSTIM1-treated cell layers were significantly different from those of siNT-treated cells, as revealed by ANOVA analysis. In contrast, Orai1 knockdown, does not affect the response intensity to thrombin or histamine (Fig. 9G, H). Neither STIM1 nor Orai1 knockdown did significantly influence ΔR values in response to S1P stimulation (Fig. 9I). Qualitatively the same results were obtained using a second set of siRNAs (siSTIM1 #2, siOrai1 #2) (Fig. 9J – O).

In summary, our statistical analysis confirmed that significant effects on GPCR-mediated changes in endothelial barrier function were only detectable upon STIM1 knockdown and only for stimulation with thrombin and histamine. STIM1 obviously plays an important role in mediating the opening of endothelial barrier upon GPCR stimulation, but its effect is independent from Ca²⁺ entry. In the following, we set out to further support our finding that HDMEC barrier breakdown is independent from extracellular Ca²⁺ rise.

Role of extracellular Ca²⁺ in GPCR-mediated endothelial barrier regulation

We have previously refrained from performing long term experiments that omit Ca²⁺ from the external solution as means to test the involvement of Ca²⁺ entry in endothelial barrier function (23). Ca²⁺ ions are required co-factors for adhesion molecules and long term removal of external Ca²⁺ will inevitably lead to gradual decrease in HDMEC monolayer resistance. Therefore, here we used a protocol involving short-term removal of external Ca²⁺ (for ~ 8 min) while monitoring changes in cytosolic Ca²⁺ in HDMEC, the monolayer resistance by ECIS and visual inspection of monolayers by fluorescence microscopy. As seen in Fig. 10, addition of thrombin in the absence of external Ca²⁺ caused an even bigger decrease in HDMEC monolayer resistance than obtained when thrombin was added in presence of external Ca²⁺ (Fig. 10A; 11 min zoom in is shown in Fig. 10B). Restoration of 2 mM Ca²⁺ to the external solution did not cause additional decrease in monolayer resistance (Fig. 10B). Fluorescence images showed the disruption of cell-cell junctions after thrombin is added in the absence of external Ca²⁺ was much more substantial than that observed in the presence of external Ca²⁺ (Fig. 10A; 11 min zoom in is shown in Fig. 10B). Restoration of 2 mM Ca²⁺ to the external solution did not cause additional decrease in monolayer resistance (Fig. 10B). Fluorescence images showed the disruption of cell-cell junctions after thrombin is added in the absence of external Ca²⁺ was much more substantial than that observed in the presence of external Ca²⁺ (Fig. 10D). This is likely due to monolayers being less stable in the absence of external Ca²⁺ as a result of weak cell-cell and cell-substrate adhesion. The Ca²⁺ response of HDMEC in the absence and presence of external Ca²⁺ showed the expected Ca²⁺ release and Ca²⁺ entry phases (Fig. 10C). Our conclusion from this experiment is that although extracellular Ca²⁺ is required for proper cell adhesion and monolayer stability and integrity, GPCR-activated Ca²⁺ entry across the plasma membrane is not required to open the endothelial barrier.
Role of Ca\textsuperscript{2+} release from internal stores in GPCR-mediated endothelial barrier regulation -

The use of Ca\textsuperscript{2+}-free extracellular solutions, SOCE inhibitors and STIM1/Orai1 molecular knockdown used thus far only prevent Ca\textsuperscript{2+} entry across the plasma membrane with no effect on Ca\textsuperscript{2+} release from IP\textsubscript{3}-sensitive stores. Therefore, we set out next to determine whether Ca\textsuperscript{2+} release from internal stores is required for changes in endothelial barrier function in acute response to GPCR agonists.

We therefore incubated HDMEC monolayers with the membrane permeant form of the fast pH-insensitive Ca\textsuperscript{2+} chelator BAPTA (BAPTA-AM). Incubation of HDMEC monolayers with 10 µM of BAPTA-AM for 10 minutes caused a substantial inhibition of both Ca\textsuperscript{2+} release and Ca\textsuperscript{2+} entry in response to thapsigargin as measured with Fura2 cytosolic Ca\textsuperscript{2+} imaging (Fig. 11A, red trace); 1 µM of BAPTA-AM had partial effects on inhibiting these thapsigargin-induced Ca\textsuperscript{2+} signals in HDMEC (Fig. 11A, blue trace) and was therefore not used any further. The incubation of HDMEC with 10 µM of BAPTA-AM for 10 minutes also substantially inhibited both Ca\textsuperscript{2+} release and Ca\textsuperscript{2+} entry in response to thrombin (Fig. 11B), histamine (Fig. 11C) and S1P (Fig. 11D). However, 10 minute pre-incubation of monolayers with 10 µM BAPTA-AM failed to inhibit the changes in endothelial barrier function in response to thrombin (Fig. 11E), histamine (Fig. 11F) and S1P (Fig. 11G). Thus, buffering of Ca\textsuperscript{2+} release from internal stores does not prevent the acute agonist-mediated changes in endothelial barrier function.

DISCUSSION

Previous work from our laboratory showed that STIM1 and Orai1 are the molecular components of SOCE in several human endothelial cell types, including endothelial cells from the umbilical vein (HUVEC), the pulmonary artery (HPAEC) and the dermal microvasculature (HDMEC) (11,23). We also showed that thrombin and vascular endothelial growth factor (VEGF) trigger Ca\textsuperscript{2+} entry into endothelial cells through SOCE and its biophysical correlate, the Ca\textsuperscript{2+} release-activated Ca\textsuperscript{2+} (CRAC) current (11,23). We performed ECIS studies using both HUVEC and HDMEC monolayers and showed that STIM1 controls thrombin-mediated disruption of endothelial barrier function independently of Orai1 and Ca\textsuperscript{2+} entry, suggesting that SOCE and Ca\textsuperscript{2+} entry in general were not required for thrombin-mediated disruption of endothelial barrier function.

In the current study, we aimed to determine whether the requirement of STIM1 and the dispensable aspect of Orai1 and Ca\textsuperscript{2+} entry in thrombin-mediated barrier disruption is generally applicable to other GPCR agonists, including those that enhance barrier function and whether Ca\textsuperscript{2+} release from internal stores is required for GPCR-mediated changes in barrier function. Thus in addition to thrombin, we chose to focus on two additional GPCR agonists, histamine which disrupts endothelial barrier function but does so with less intensity and quicker recovery time than thrombin, and S1P which enhances endothelial barrier function. We found that all three GPCR agonists, thrombin, histamine and S1P activate Ca\textsuperscript{2+} entry which displays the typical pharmacological profiles of SOCE. Inhibition of SOCE and Ca\textsuperscript{2+} entry in general with lanthanides or BTP2 had no effects on changes in barrier function caused by all three GPCR agonists. However, the uses of 25 µM 2-APB (a concentration that inhibits Ca\textsuperscript{2+} entry with no effect on Ca\textsuperscript{2+} release) inhibited thrombin- and histamine-mediated disruption of barrier function with no effect on S1P-mediated enhancement of barrier function. In light of the results obtained with Gd\textsuperscript{3+} and BTP2, the effect of 2-APB is likely unrelated to its ability of inhibiting Ca\textsuperscript{2+} entry. 2-APB was shown to inhibit STIM1 function by preventing STIM1 aggregation and

Downloaded from http://www.jbc.org/ by guest on March 24, 2020
movements in response to store depletion (40), which is consistent with our STIM1 molecular knockdown inhibiting barrier disruption in response to thrombin and histamine. STIM1 knockdown had no effect on the barrier-stabilizing function of S1P, suggesting that STIM1 plays a role in processes involving disruption of barrier function but not in the molecular pathways that control stabilization of endothelial barrier function. Knockdown of Orai1 failed to affect the disruption of barrier function in response to thrombin and histamine and had no bearing on the enhancement of barrier function in response to S1P.

We also showed that the use of a fast cytosolic Ca\(^{2+}\) buffer, BAPTA-AM on endothelial monolayers led to a strong inhibition of the Ca\(^{2+}\) release and Ca\(^{2+}\) entry signals in response to thapsigargin and GPCR agonists. Yet, this Ca\(^{2+}\) buffering failed to affect the typical response of endothelial monolayers to thrombin, histamine and S1P, strongly arguing that Ca\(^{2+}\) release and Ca\(^{2+}\) entry are not necessary for GPCR-mediated changes in endothelial barrier function. These results are consistent with previous studies showing that thrombin-mediated disruption of endothelial barrier function occurs independently of \(G_{q}\)-mediated Ca\(^{2+}\) signaling (44), and a recent study showing that histamine-mediated disruption of endothelial barrier function requires RhoA and ROCK, while phospholipase C pharmacological inhibition had a marginal effect (45). Our previous studies showed that knockdown of STIM1 caused inhibition of RhoA activity and MLC phosphorylation in response to thrombin. We also showed that STIM1 knockdown led to increased basal phosphorylation of FAK and paxillin, consistent with a role for STIM1 in mediating GPCR-induced endothelial barrier disruption through RhoA independently of receptor-activated Ca\(^{2+}\) signaling (23). Likewise, the stabilizing effects of S1P on barrier function occur via Rac-mediated pathways and are independent of STIM1, Orai1 and Ca\(^{2+}\) signaling. Collectively, data in the literature supports that regulation of endothelial barrier disruption and stabilization is likely mediated by the balance between the activities of Rho and Rac/Cdc42.

The “increased cytosolic Ca\(^{2+}\)-induced endothelial contraction” hypothesis stipulates that Ca\(^{2+}\) entry upon GPCR ligation activates MLCK which in turn phosphorylates MLC to cause endothelial contraction and disruption of barrier function (3,18,21). Earlier studies which proposed a role for MLCK in controlling endothelial barrier function downstream GPCR agonists relied on nonspecific approaches such as the use of MLCK inhibitory peptides or MLCK pharmacological inhibitors, namely ML7 and ML9 (46-48). Subsequently, ML9 was shown to inhibit STIM1 aggregation and movement upon store depletion in an MLCK-independent manner (40). Work in our laboratory showed that effective knockdown of endothelial MLCK failed to alter the disruption of endothelial barrier function in response to thrombin, ruling out the requirement of MLCK in GPCR-mediated acute control of barrier function (23).

Other Ca\(^{2+}\)-sensitive enzymes, including Ca\(^{2+}\)/Calmodulin-dependent kinase II (CaMKII) and protein kinase C (PKC), were proposed to regulate the cell-cell Junctional VE-cadherin/catenin complex disassembly in endothelial cells in response to thrombin (49-55). For instance, the endothelial CaMKII\(\delta\) isoform was shown to play a role in thrombin-mediated endothelial barrier disruption. However, CaMKII\(\delta\) contribution was through RhoA/ROCK-dependent mechanism and was apparent only at low concentrations of thrombin (2.5 nM) where the Ca\(^{2+}\) signal activated by thrombin was negligible, but not at higher concentrations of thrombin (56). Therefore, increased cytosolic Ca\(^{2+}\) and MLCK are not absolutely required for
triggering the acute and rapid disruption in barrier function in response to GPCR agonists; RhoA activation appears necessary and sufficient. However, we cannot obviously rule out subtle regulatory roles for cytosolic Ca\(^{2+}\) and MLCK (or other Ca\(^{2+}\)-activated enzymes) during the signaling processes impacting on cytoskeletal rearrangements such as endothelial permeability or migration. In most in vivo studies, Ca\(^{2+}\) signals and endothelial permeability to agonists, measured for instance on mesenteric venules of anaesthetized rats, are merely correlative and are based on the use of pharmacological compounds with questioned specificity (57-59). However, a regulatory role for cytosolic Ca\(^{2+}\) rise and subcellular activation of Ca\(^{2+}\)-activated enzymes in endothelial barrier function might be more significant under in vivo conditions which are more complex and where subtle rearrangements of the barrier at specific sites are sufficient to allow passage of cells and solutes. We are arguing herein that the idea of acute and rapid changes in endothelial barrier function being triggered by a Ca\(^{2+}\) signal in a manner analogous to contraction of smooth muscle is not supported by the evidence and therefore the model of “Ca\(^{2+}\)-induced endothelial contraction” should be abandoned.

**EXPERIMENTAL PROCEDURES**

**Reagents**- siRNA sequences siSTIM1 (#1: AAGGGAAGACCUCAAUUACCAUU, #2: GGUGGGUGUCUA UCGUUAAUUU), siOrai1 (#1: CUGUCC UCUAAGAGAAUAAUU, #2: CGUGCACAUCUAACUCGUU) and non-targeting siControl (UGGUUUACAGUGCGCUAUAU) were from Dharmacon Scientific. Anti-Orai1 (rabbit) antibody was from Sigma (cat. no. G8795), used at a dilution of 1:1000. Anti-GAPDH (mouse) is from Sigma (cat. no. G8795), used at a dilution of 1:3000 and anti-HSP 70/HSC 70 (W27) (mouse) from Santa Cruz Biotechnology (cat. No. sc-24) was used at a dilution of 1:2000. Anti-rabbit IgG-HRP and anti-mouse IgG-HRP are from Calbiochem used at 1:10,000. Anti-VE-Cadherin (goat) antibody used for immunofluorescence was purchased from Santa Cruz Biotechnology and used at 1:200. Secondary Alexa Fluor 594®-labelled anti goat antibody (rabbit) is from Molecular Probes, used at 1:250. Alexa Fluor 488® phalloidin is from Molecular Probes. BCA Protein Assay Kit, Super Signal West Pico, West Femto and Restore Western Blot Stripping Buffer were from Pierce Biotechnology (Rockford, IL). All other chemicals were purchased from Fisher Scientific (Pittsburgh, PA) unless specified otherwise.

**Cell Culture**- Human Dermal Microvascular endothelial cells (HDMEC), were isolated from human neonatal foreskin and purified by CD31 antibody-coated magnetic beads (DYNAL®) as described elsewhere (60). Endothelial origin was tested by VE-cadherin and Lectin staining. Cells were cultured in EBM2 basal medium (Lonza, Walkersville, cat. no. CC-3156) supplemented with EGM2-MV bullet kit for microvascular endothelial cells (Lonza, cat. no. CC-4147), 2 mM L-Glutamine (Thermo Fisher Scientific, HyClone™, cat. no. SH30034.01) and Antibiotic-Antimycotic (Gibco®, Life Technologies, cat. no. 15240-062). Cells were subcultured every 3 – 4 days when at 90 % confluence by trypsination (0.05% Trypsin / 0.53 mM EDTA in HBSS from Corning, cellgro®, cat. no. 25-052- CI) and used up to passage 12.

For Impedance measurements, cells were grown onto ECIS cultureware arrays from Applied BioPhysics Inc. (Troy, NY). If not specified otherwise electrode type 8W10E+
Calcium signaling and barrier function

PET were used. Other Array types used were 96w20idf PET and 2W4x10E PC. Before use, Arrays were treated with sterile filtered 10 mM Cysteine in water for 10 min in order to generate stable electrode impedance. Afterwards electrodes were rinsed three times with sterile water and coated with 300 µL of 0.2 % gelatin in PBS (8.0 g/L NaCl, 0.2 g/L KCl, 1.42 g/L Na₂HPO₄ and 0.24 g/L KH₂PO₄ pH 7.4) for 10 minutes (gelatin was purchased from Acros organics, gelatin for analysis, granular, cat. no. AC410875000, cas 9000-70-8). HDMEC were seeded onto the ECIS cultureware at a density of 100,000 cells/cm² in 400 µL complete medium. To allow uniform settling of cells at the bottom of the wells, the arrays were left for ~ 10 min on the bench. Cells were maintained in culture for 2 – 4 days (depending on the agonist studied, see below) in a humidified incubator with 5 % CO₂ at 37 °C. Every 24 h half of the medium was exchanged by removing 200 µL old medium and adding back 200 µL fresh medium. Exchanging only 50 % of medium instead of a full exchange reduces mechanical stress on the cell layer. Without media changes the cell layers established lower baseline resistances and higher variability in baseline values as well as in kinetics of response to agonists. 6 – 24 h before the experiment complete medium was exchanged with low serum (0.3 %) medium.

siRNA Transfections- For specific knockdown of STIM1 and Orai1 we used siRNA sequences (see Reagents) that have been established and tested for knockdown efficiency as previously described (11,23). Transfections with siRNA sequences were performed with the Amaza 4D-Nucleofector® (Lonza, Amaza Biosystems) using transfection solution P5 and the program EH100, following the manufacturer’s instructions. 0.5 µg of GFP plasmid construct (Amaza) was co-transfected with siRNA to control transfection efficiency, which typically exceeded 80 %. Protein knockdown efficiency was quantified by western blot.

For Impedance measurements transfected cells were directly seeded onto the gelatin-coated electrodes for thrombin or histamine experiments. For S1P experiments where two day old cell layers were used, cells were first grown for two days on regular culture flasks, before seeding for impedance measurements.

Impedance measurements- Impedance measurements were performed using the Electric Cell-substrate Impedance Sensing (ECIS) Zθ machine (Applied BioPhysics Inc. Troy, NY) with an array holder station for two 8-well arrays of type 8W10E+ (or 2W4x1E PC) and an alternative 96-well plate holder for 96W20idf type electrode arrays (26). Measurements were performed in a humidified cell culture incubator unless stated otherwise. Barrier function of HDMEC cell layers was measured at 4000 Hz when using 8W10E+ electrodes or at 2000 Hz when using 96W20idf electrode arrays, which were the respective frequencies with maximum dynamic range between the cell-free and cell-covered electrodes (26). Single frequency time collect (SFT) mode allowed detecting HDMEC response to GPCR agonists with a time resolution of 8 seconds for 16 wells, or 48 seconds for 96 wells, respectively. For data presentation the resistance, the real part of the impedance data, which is most indicative of paracellular currents via cell-cell junctions was normalized to the last value before agonist addition (normalized resistance) and plotted versus time. For measurements of the complete attachment, growth and cell layer maturation process electrodes were pre-treated with 10 mM cysteine solution one day before cell seeding. After 10 min incubation with 150 µL cysteine solution, arrays were rinsed three times with water and incubated in HDMEC medium overnight to support establishment of stable electrode-electrolyte interface. HDMEC attachment, spreading and cell layer maturation was measured with multiple
frequency time (MFT) collect mode. A baseline of the cell-free array with 400 µL medium in each well was measured over at least 1 h. Data acquisition was paused for inoculation with single-cell suspension (100,000 cells/cm²) and for media changes.

Monitoring of HDMEC Response to GPCR Agonists- Thrombin (cat. No. T464), histamine (cat. no. 53300) and S1P (cat. no. A8806) were purchased from Sigma-Aldrich. Thrombin stock solutions in MilliQ water (100 µM) were stored at −80 °C. Immediately before use in an experiment, 100 nmol/L working solution (for a final concentration of 5 nmol/L, 20 µL per well) was prepared in pre-warmed 0.3 % serum medium (50 mL EBM-2 150 µL FBS, 500 µL 100 × Antibiotics-Antimycotics and 500 µL 100 × L-Glutamine solution). 1 mol/L histamine stock solutions in MilliQ water were stored at −20 °C. Before use, a 200 µmol/L working 20 × solution was prepared in serum-free medium (for a final concentration of 10 µmol/L and addition of 20 µL per well). Soluwas pre-warmed to 37 °C for about 5 min before addition to the cells. S1P was solubilized in methanol, aliquoted, dried under nitrogen and stored at −20 °C. For use in stimulation experiments, 20 µM S1P (20 ×) working solution was made in HBSS (Fisher Scientific, cat. no. 14025-092) with 0.03 mg/mL fatty acid-free BSA (from bovine plasma, Sigma-Aldrich, cat. no. A8806). Solubilization was supported by brief sonication for 5 min at 37 °C. For experiments with thrombin, HDMEC cell layers were used after 4 days in culture. Cells were changed to serum-free medium 12–24 h before start of the experiment. Cell layer quality was checked by phase contrast microscopy and by either recording a single full impedance spectrum or collecting data for 10–30 min at MFT mode. The resistance at 4000 Hz should be in the range of 2500–4500 Ω for HDMEC grown on 8W10E+ electrodes for 4 d. On 96W20idf the resistance at 2000 Hz should be above 1000 Ω; if these basal resistances were not attained, the experiment was aborted. A baseline was recorded for at least 10 minutes. Thrombin was added as a 20 × stock solution. While the measurement was running, 20 µL of old medium were removed from the initial 400 µL of each well. 20 µL of 20 × thrombin solution (100 nmol/L) were then added to the remaining 380 mL to give a final concentration of 5 nmol/L. Cell responses was monitored for at least 1 h after addition of thrombin. For experiments with histamine, HDMEC cell layers were used after 3–4 days in culture. Cells were changed to serum-free medium 6–12 h before start of the experiment. Histamine was added as a 20 × stock solution of 200 µmol/L histamine in low serum medium, following the procedure as described for thrombin. For S1P experiments HDMEC were used after 2 days in culture, where cell layers were confluent, but cell-cell junctions were not fully mature (26). Cells were changed to serum-free medium 6 h before stimulation with 1 µM S1P. The experiment was conducted as described above for thrombin and histamine, using a 20 × stock solution. For ECIS experiments using pre-incubation with Gd3+ and corresponding controls, a HEPES-based medium was used (130 mM NaCl, 3 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 5 mM glucose, and 20 mM Na-HEPES pH 7.4) as previously described (23).

Calcium Imaging- For measuring changes in intracellular Calcium, HDMECs were grown on gelatin coated 30 mm round coverslips as previously described (61–63). Coverslips with cells were mounted in a Teflon chamber and incubated with 4 µM Fura-2/AM in culture medium for 35 min at 37°C protected from light. Afterwards, cells were gently washed three times with HEPES-buffered saline (140 mM NaCl, 1.13 mM MgCl₂, 4.7 mM KCl, 2 mM CaCl₂, 10 mM D-Glucose, and 10 mM HEPES, pH 7.4) and let sit for 10 min at room temperature and protected from light. Data acquisition was performed using InCyt...
Im2 Fluorescence Imaging System and IntCyt Im2 software (Intracellular Imaging Inc., Cincinnati, OH). Fura-2 loaded cells were alternately illuminated with 340 and 380 nm. Fluorescence emission was collected at 510 nm. 340/380 ratio images were obtained on pixel-by-pixel basis. Figures showing Ca^{2+} traces are an average from several cells per coverslip and are a representative of several independent recordings of several cells as indicated in the respective figure legends. Thrombin and histamine solutions were made in HEPES buffered saline, and S1P solutions additionally contained 0.03 mg/mL fatty acid-free BSA.

**Immunofluorescence Staining**- HDMEC were grown on gelatin coated cover glasses for four days (initial seeding density 100,000 cells/cm^2). Cell layers were stimulated with different agonists under the same conditions as used for ECIS experiments. At the indicated time after stimulation cells were fixed with 4 % (w/v) paraformaldehyde (PFA) in PBS for 20 min. Fixed cells were rinsed with PBS three times and permeabilized with 0.02 % Triton-X100 in PBS. Permeabilized cells were first treated with Image-iT® FX signal enhancer (Fisher Scientific, cat. no. I36933) for 30 min and afterwards blocked with a mixture of 3 % BSA and 5 % serum in Tris buffered saline (TBS) for 1 h. Cell layers were rinsed two times before incubated with goat anti-VE-cadherin primary antibody (1:200) in PBS for 2 h at room temperature. Secondary antibody (Alexa Fluor 594®-labelled rabbit anti goat antibody from Molecular Probes) incubation was for 1 h at room temperature together with Alexa Fluor 488® Phalloidin and Hoechst 33342 incubation. Cells were rinsed three times and embedded with anti-fade mounting medium (Sigma-Aldrich). Images were taken on a Zeiss confocal microscope.

**Western Blotting**- Cells were transfected with respective siRNAs as described above. After 4 days cells were lysed in RIPA lysis buffer (Sigma Aldrich) with 10 % protease inhibitor cocktail and 10 % phosphatase inhibitor cocktail (both from Roche Diagnostics). Suspensions were subjected to a 30 s sonication on ice. Cell debris were removed by 1.5 min centrifugation at 14,000 rpm and 4 °C. Protein concentration in the supernatant was determined using BCA assay (Pierce) and SpectraMax® Paradigm® Multi-Mode Detection Platform (Molecular Devices) and equal amounts of proteins were loaded in each well. Lysates (50 µg per well) were subjected to SDS-PAGE electrophoresis using the Precision Plus™ Protein Dual Color Standard (Bio-Rad) as reference (with 10, 15, 20, 25, 37, 50, 75, 100, 150, 250 kDa) and transferred to immuno-BLOT PVDF membranes (Bio-Rad). Membranes were blocked (5 % non-fat milk/TBS/Tween-20) at 4 °C overnight, incubated with respective antibodies, washed and subsequently incubated with horseradish peroxidase (HRP)-linked secondary antibody in 2 % non-fat milk/TBS/Tween-20 for 2 h. Bound antibody was detected by enhanced chemiluminescence with Super Signal West Pico or Femto reagents (Pierce). Signal intensity was measured using a Bio-Rad ChemiDoc MP imaging system (Bio-Rad). Membranes were then stripped and reprobed with anti-βactin, anti-GAPDH or anti-HSP 70/HSC 70 antibody to verify equal protein loading. Quantitative densitometry analysis was performed using ImageJ software.

**Statistical Analysis**- Experimental data are presented as mean ± SD. Only for data sets with very high N-numbers mean ± SE was used and is indicated as such in the figure legend. To test for statistical significance data sets were subjected to ANOVA analysis. Levels of significance were indicated with asterisks as follows: * < 0.05, ** < 0.01, *** < 0.005. A p-value of < 0.05 was considered statistically significant. ANOVA analysis and Pearson’s correlation calculations were
performed with OriginLab Pro software. Density plots were generated with R software using Kernel density smoothing for histograms (https://stat.ethz.ch/R-manual/R-devel/library/stats/html/density.html). All data were plotted using Origin Pro software.

ACKNOWLEDGMENTS
This work was supported by AHA grant 14GRNT18880008 and NIH grants R01HL097111 and R01HL123364 to Mohamed Trebak, and in part by a postdoctoral fellowship from Applied Biophysics Inc. (Troy, NY) to Judith A. Stolwijk and grant R01HL095566 from the NIH to Khalid Matrougui.

CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest with the contents of this article.

AUTHOR CONTRIBUTIONS
J.A.S. and M.T. designed research, analyzed data and drafted the manuscript. J.A.S performed most of research. X.Z, W.Z. and M.G. performed part of the experiments and analyzed data. C.R. analyzed data statistically, provided reagents and arrays, technical assistance and critical input on the manuscript. K.M. provided reagents, technical assistance and critical input on overall research. All authors discussed and approved the manuscript.

REFERENCES
1. Amado-Azevedo, J., Valent, E. T., and Van Nieuw Amerongen, G. P. (2014) Regulation of the endothelial barrier function: a filum granum of cellular forces, Rho-GTPase signaling and microenvironment. Cell and tissue research 355, 557-576
2. Beckers, C. M., van Hinsbergh, V. W., and van Nieuw Amerongen, G. P. (2010) Driving Rho GTPase activity in endothelial cells regulates barrier integrity. Thrombosis and haemostasis 103, 40-55
3. Mehta, D., and Malik, A. B. (2006) Signaling mechanisms regulating endothelial permeability. Physiol Rev 86, 279-367
4. van Nieuw Amerongen, G. P., Musters, R. J., Eringa, E. C., Sipkema, P., and van Hinsbergh, V. W. (2008) Thrombin-induced endothelial barrier disruption in intact microvessels: role of RhoA/Rho kinase-myosin phosphatase axis. American journal of physiology. Cell physiology 294, C1234-1241
5. Terry, S., Nie, M., Matter, K., and Balda, M. S. (2010) Rho signaling and tight junction functions. Physiology 25, 16-26
6. Amano, M., Ito, M., Kimura, K., Fukata, Y., Chihara, K., Nakano, T., Matsuura, Y., and Kaibuchi, K. (1996) Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). The Journal of biological chemistry 271, 20246-20249
7. Garcia, J. G., Liu, F., Verin, A. D., Birukova, A., Dechert, M. A., Gerthoffer, W. T., Bamberg, J. R., and English, D. (2001) Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. The Journal of clinical investigation 108, 689-701
8. Kolodney, M. S., and Wysolmerski, R. B. (1992) Isometric contraction by fibroblasts and endothelial cells in tissue culture: a quantitative study. The Journal of cell biology 117, 73-82
9. Putney, J. W., Jr. (1986) A model for receptor-regulated calcium entry. *Cell calcium* 7, 1-12
10. Trebak, M. (2009) STIM1/Orai1, ICRAC, and endothelial SOC. *Circulation research* 104, e56-57
11. Abdullaev, I. F., Bisaiillon, J. M., Potier, M., Gonzalez, J. C., Motiani, R. K., and Trebak, M. (2008) Stim1 and Orai1 mediate CRAC currents and store-operated calcium entry important for endothelial cell proliferation. *Circulation research* 103, 1289-1299
12. Zhou, M. H., Zheng, H., Si, H., Jin, Y., Peng, J. M., He, L., Zhou, Y., Munoz-Garay, C., Zawieja, D. C., Kuo, L., Peng, X., and Zhang, S. L. (2014) Stromal interaction molecule 1 (STIM1) and Orai1 mediate histamine-evoked calcium entry and nuclear factor of activated T-cells (NFAT) signaling in human umbilical vein endothelial cells. *The Journal of biological chemistry* 289, 29446-29456
13. Potier, M., and Trebak, M. (2008) New developments in the signaling mechanisms of the store-operated calcium entry pathway. *Pflugers Archiv : European journal of physiology* 457, 405-415
14. Moccia, F., Tanzi, F., and Munaron, L. (2014) Endothelial remodelling and intracellular calcium machinery. *Current molecular medicine* 14, 457-480
15. Fahrner, M., Derler, I., Jardin, I., and Romanin, C. (2013) The STIM1/Orai signaling machinery. *Channels* 7, 330-343
16. Rosado, J. A., Diez, R., Smani, T., and Jardin, I. (2015) STIM and Orai1 Variants in Store-Operated Calcium Entry. *Frontiers in pharmacology* 6, 325
17. Putney, J. W. (2011) Origins of the concept of store-operated calcium entry. *Frontiers in bioscience* 3, 980-984
18. Cioffi, D. L., and Stevens, T. (2006) Regulation of endothelial cell barrier function by store-operated calcium entry. *Microcirculation* 13, 709-723
19. Cioffi, D. L., Lowe, K., Alvarez, D. F., Barry, C., and Stevens, T. (2009) TRPing on the lung endothelium: calcium channels that regulate barrier function. *Antioxid Redox Signal* 11, 765-776
20. Moore, T. M., Norwood, N. R., Creighton, J. R., Babal, P., Brough, G. H., Shasby, D. M., and Stevens, T. (2000) Receptor-dependent activation of store-operated calcium entry increases endothelial cell permeability. *American journal of physiology. Lung cellular and molecular physiology* 279, L691-698
21. Shen, Q., Rigor, R. R., Pivetti, C. D., Wu, M. H., and Yuan, S. Y. (2010) Myosin light chain kinase in microvascular endothelial barrier function. *Cardiovascular research* 87, 272-280
22. Mehta, D., Konstantoulaki, M., Ahmmed, G. U., and Malik, A. B. (2005) Sphingosine 1-phosphate-induced mobilization of intracellular Ca2+ mediates rac activation and adherens junction assembly in endothelial cells. *The Journal of biological chemistry* 280, 17320-17328
23. Shinde, A. V., Motiani, R. K., Zhang, X., Abdullaev, I. F., Adam, A. P., Gonzalez-Cobos, J. C., Zhang, W., Matrougui, K., Vincent, P. A., and Trebak, M. (2013) STIM1 controls endothelial barrier function independently of Orai1 and Ca2+ entry. *Sci Signal* 6, ra18
24. Li, J., Cubbon, R. M., Wilson, L. A., Amer, M. S., McKeown, L., Hou, B., Majeed, Y., Tumova, S., Seymour, V. A., Taylor, H., Stacey, M., O'Regan, D., Foster, R., Porter, K. E., Kearney, M. T., and Beech, D. J. (2011) Orai1 and CRAC channel dependence of VEGF-activated Ca2+ entry and endothelial tube formation. *Circulation research* 108, 1190-1198
25. Antigny, F., Jousset, H., König, S., and Frieden, M. (2011) Thapsigargin activates Ca(2)+ entry both by store-dependent, STIM1/Orai1-mediated, and store-independent, TRPC3/PLC/PKC-mediated pathways in human endothelial cells. *Cell calcium* 49, 115-127

26. Stolwijk, J. A., Matrougui, K., Renken, C. W., and Trebak, M. (2015) Impedance analysis of GPCR-mediated changes in endothelial barrier function: overview and fundamental considerations for stable and reproducible measurements. *Pflugers Archiv : European journal of physiology* 467, 2193-2218

27. Trebak, M. (2012) STIM/Orai signalling complexes in vascular smooth muscle. *The Journal of physiology* 590, 4201-4208

28. Prakriya, M., and Lewis, R. S. (2015) Store-Operated Calcium Channels. *Physiol Rev* 95, 1383-1436

29. Takemura, H., Hughes, A. R., Thastrup, O., and Putney, J. W., Jr. (1989) Activation of calcium entry by the tumor promoter thapsigargin in parotid acinar cells. Evidence that an intracellular calcium pool and not an inositol phosphate regulates calcium fluxes at the plasma membrane. *The Journal of biological chemistry* 264, 12266-12271

30. Trebak, M., St, J. B. G., McKay, R. R., Birnbaumer, L., and Putney, J. W., Jr. (2003) Signaling mechanism for receptor-activated canonical transient receptor potential 3 (TRPC3) channels. *The Journal of biological chemistry* 278, 16244-16252

31. Trebak, M., Bird, G. S., McKay, R. R., and Putney, J. W., Jr. (2002) Comparison of human TRPC3 channels in receptor-activated and store-operated modes. Differential sensitivity to channel blockers suggests fundamental differences in channel composition. *The Journal of biological chemistry* 277, 21617-21623

32. He, L. P., Hewavitharana, T., Soboloff, J., Spassova, M. A., and Gill, D. L. (2005) A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2. *The Journal of biological chemistry* 280, 10997-11006

33. Law, M., Morales, J. L., Mottram, L. F., Iyer, A., Peterson, B. R., and August, A. (2011) Structural requirements for the inhibition of calcium mobilization and mast cell activation by the pyrazole derivative BTP2. *Int J Biochem Cell Biol* 43, 1228-1239

34. Ohga, K., Takezawa, R., Arakida, Y., Shimizu, Y., and Ishikawa, J. (2008) Characterization of YM-58483/BTP2, a novel store-operated Ca2+ entry blocker, on T cell-mediated immune responses in vivo. *Int Immunopharmacol* 8, 1787-1792

35. Zitt, C., Strauss, B., Schwarz, E. C., Spaeth, N., Rast, G., Hatzelmann, A., and Hoth, M. (2004) Potent inhibition of Ca2+ release-activated Ca2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2. *The Journal of biological chemistry* 279, 12427-12437

36. DeHaven, W. I., Smyth, J. T., Boyles, R. R., Bird, G. S., and Putney, J. W., Jr. (2008) Complex actions of 2-aminoethyldiphenyl borate on store-operated calcium entry. *The Journal of biological chemistry* 283, 19265-19273

37. Bootman, M. D., Collins, T. J., Mackenzie, L., Roderick, H. L., Berridge, M. J., and Peppiatt, C. M. (2002) 2-aminoethoxydiphenyl borate (2-APB) is a reliable blocker of store-operated Ca2+ entry but an inconsistent inhibitor of InsP3-induced Ca2+ release. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 16, 1145-1150
38. Prakriya, M., and Lewis, R. S. (2001) Potentiation and inhibition of Ca(2+) release-activated Ca(2+) channels by 2-aminoethylidiphenyl borate (2-APB) occurs independently of IP(3) receptors. *The Journal of physiology* **536**, 3-19

39. Takezawa, R., Cheng, H., Beck, A., Ishikawa, J., Launay, P., Kubota, H., Kinet, J. P., Fleig, A., Yamada, T., and Penner, R. (2006) A pyrazole derivative potently inhibits lymphocyte Ca2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 channel activity. *Mol Pharmacol* **69**, 1413-1420

40. Smyth, J. T., Dehaven, W. I., Bird, G. S., and Putney, J. W., Jr. (2008) Ca2+-store-dependent and -independent reversal of Stim1 localization and function. *Journal of cell science* **121**, 762-772

41. Motiani, R. K., Abdullaev, I. F., and Trebak, M. (2010) A novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells. *The Journal of biological chemistry* **285**, 19173-19183

42. Motiani, R. K., Hyzinski-Garcia, M. C., Zhang, X., Henkel, M. M., Abdullaev, I. F., Kuo, Y. H., Matrougui, K., Mongin, A. A., and Trebak, M. (2013) STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. *Pflugers Archiv : European journal of physiology* **465**, 1249-1260

43. Motiani, R. K., Zhang, X., Harmon, K. E., Keller, R. S., Matrougui, K., Bennett, J. A., and Trebak, M. (2013) Orai3 is an estrogen receptor alpha-regulated Ca(2)(+) channel that promotes tumorigenesis. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* **27**, 63-75

44. McLaughlin, J. N., Shen, L., Holinstat, M., Brooks, J. D., Dibenedetto, E., and Hamm, H. E. (2005) Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. *The Journal of biological chemistry* **280**, 25048-25059

45. Mikelis, C. M., Simaan, M., Ando, K., Fukuhara, S., Sakurai, A., Amornphimoltham, P., Masedunskas, A., Weigert, R., Chavakis, T., Adams, R. H., Offermanns, S., Mochizuki, N., Zheng, Y., and Gutkind, J. S. (2015) RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock. *Nature communications* **6**, 6725

46. Yuan, S. Y., Wu, M. H., Ustinova, E. E., Guo, M., Tinsley, J. H., De Lanerolle, P., and Xu, W. (2002) Myosin light chain phosphorylation in neutrophil-stimulated coronary microvascular leakage. *Circulation research* **90**, 1214-1221

47. Tinsley, J. H., De Lanerolle, P., Wilson, E., Ma, W., and Yuan, S. Y. (2000) Myosin light chain kinase transference induces myosin light chain activation and endothelial hyperpermeability. *American journal of physiology. Cell physiology* **279**, C1285-1289

48. Norwood, N., Moore, T. M., Dean, D. A., Bhattacharjee, R., Li, M., and Stevens, T. (2000) Store-operated calcium entry and increased endothelial cell permeability. *American journal of physiology. Lung cellular and molecular physiology* **279**, L815-824

49. Borbiev, T., Verin, A. D., Birukova, A., Liu, F., Crow, M. T., and Garcia, J. G. (2003) Role of CaM kinase II and ERK activation in thrombin-induced endothelial cell barrier dysfunction. *American journal of physiology. Lung cellular and molecular physiology* **285**, L43-54

50. Borbiev, T., Verin, A. D., Shi, S., Liu, F., and Garcia, J. G. (2001) Regulation of endothelial cell barrier function by calcium/calmodulin-dependent protein kinase II. *American journal of physiology. Lung cellular and molecular physiology* **280**, L983-990
51. Sandoval, R., Malik, A. B., Naqvi, T., Mehta, D., and Tiruppathi, C. (2001) Requirement for Ca2+ signaling in the mechanism of thrombin-induced increase in endothelial permeability. *American journal of physiology. Lung cellular and molecular physiology* **280**, L239-247

52. Sandoval, R., Malik, A. B., Minshall, R. D., Kouklis, P., Ellis, C. A., and Tiruppathi, C. (2001) Ca(2+) signalling and PKCalpha activate increased endothelial permeability by disassembly of VE-cadherin junctions. *The Journal of physiology* **533**, 433-445

53. Mehta, D., Rahman, A., and Malik, A. B. (2001) Protein kinase C-alpha signals rho- guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function. *The Journal of biological chemistry* **276**, 22614-22620

54. Konstantoulaki, M., Kouklis, P., and Malik, A. B. (2003) Protein kinase C modifications of VE-cadherin, p120, and beta-catenin contribute to endothelial barrier dysregulation induced by thrombin. *American journal of physiology. Lung cellular and molecular physiology* **285**, L434-442

55. Janmey, P. A. (1994) Phosphoinositides and calcium as regulators of cellular actin assembly and disassembly. *Annu Rev Physiol* **56**, 169-191

56. Wang, Z., Ginnan, R., Abdullaev, I. F., Trebak, M., Vincent, P. A., and Singer, H. A. (2010) Calcium/Calmodulin-dependent protein kinase II delta 6 (CaMKIIdelta6) and RhoA involvement in thrombin-induced endothelial barrier dysfunction. *The Journal of biological chemistry* **285**, 21303-21312

57. Zhu, L., and He, P. (2005) Platelet-activating factor increases endothelial [Ca2+]i and NO production in individually perfused intact microvessels. *American journal of physiology. Heart and circulatory physiology* **288**, H2869-2877

58. Yuan, D., Xu, S., and He, P. (2014) Enhanced permeability responses to inflammation in streptozotocin-induced diabetic rat venules: Rho-mediated alterations of actin cytoskeleton and VE-cadherin. *American journal of physiology. Heart and circulatory physiology* **307**, H44-53

59. Zhou, X., and He, P. (2011) Temporal and spatial correlation of platelet-activating factor-induced increases in endothelial [Ca(2)(+)]i, nitric oxide, and gap formation in intact venules. *American journal of physiology. Heart and circulatory physiology* **301**, H1788-1797

60. Ferreri, D. M., Minnear, F. L., Yin, T., Kowalczyk, A. P., and Vincent, P. A. (2008) N-cadherin levels in endothelial cells are regulated by monolayer maturity and p120 availability. *Cell Commun Adhes* **15**, 333-349

61. Kassan, M., Zhang, W., Aissa, K. A., Stolwijk, J., Trebak, M., and Matrougui, K. (2014) Differential role for stromal interacting molecule 1 in the regulation of vascular function. *Pflugers Archiv : European journal of physiology*

62. Bisaillon, J. M., Motiani, R. K., Gonzalez-Cobos, J. C., Potier, M., Halligan, K. E., Alzawahra, W. F., Barroso, M., Singer, H. A., Jourd'heuil, D., and Trebak, M. (2010) Essential role for STIM1/Orai1-mediated calcium influx in PDGF-induced smooth muscle migration. *American journal of physiology. Cell physiology* **298**, C993-1005

63. Gonzalez-Cobos, J. C., Zhang, X., Zhang, W., Ruhle, B., Motiani, R. K., Schindl, R., Muik, M., Spinelli, A. M., Bisaillon, J. M., Shinde, A. V., Fahrner, M., Singer, H. A., Matrougui, K., Barroso, M., Romanin, C., and Trebak, M. (2013) Store-independent Orai1/3 channels activated by intracrine leukotriene C4: role in neointimal hyperplasia. *Circulation research* **112**, 1013-1025
FOOTNOTES
The abbreviations used are: GPCR, G Protein-Coupled Receptors; S1P, Sphingosine-1 Phosphate; STIM1, Stromal Interacting molecule-1; HDMEC, human dermal microvascular endothelial cells; ECIS, Electric Cell-substrate Impedance Sensing; 2-APB, 2-Aminoethoxydiphenyl borate; BTP2, \( N\)-[4-[3,5-Bis(trifluoromethyl)pyrazol-1-yl]phenyl]-4-methylthiadiazole-5-carboxamide; BAPTA-AM, 1,2-bis(o-aminophenoxy)ethane-N,N N',N'-tetraacetic acid-acetoxymethyl ester

FIGURE LEGENDS
FIGURE 1- Typical responses of HDMEC to GPCR agonists thrombin, histamine and S1P. (A – C) Electrical resistance of confluent HDMEC cell layers after stimulation with (A) 5 nM thrombin, (B) 10 µM histamine and (C) 1 µM S1P where indicated by arrows. Electrical resistance was normalized to the last values before agonist addition. Absolute Baseline resistances were: (A) 4202 Ω, (B) 3841 Ω and (C) 2198 Ω. Note, that for thrombin and histamine stimulation mature HDMEC cell layers were used after 4 days in culture, whereas S1P experiments were intentionally conducted with cell layers after 2 days in culture which explains the lower initial baseline resistance. S1P experiments were performed in less mature HDMEC monolayers to better resolve S1P-mediated enhancement of barrier function. (D) Confocal fluorescence images of confluent HDMEC cell layers 2 min after stimulation with thrombin, histamine or S1P compared to the control. Cells were stained for VE-cadherin (red), actin (green) and Hoechst 33342 (blue). (E – I) Kinetics of changes in HDMEC cell layer morphology and junctions after 5 nM thrombin and 10 µM histamine stimulation were followed at different time points as indicated by red arrows in ECIS traces (E, F). Thrombin and histamine addition, respectively, is indicated by black arrows. Distribution of VE-cadherin and actin is shown for the selected time points after thrombin (G) or histamine (H) stimulation and compared to an untreated control (I). White arrows point to areas with increased amount of actin bundles and fiber structures. Asterisks indicate cells used for quantification of actin and VE-cadherin distribution in (J). (J) Quantification of actin (green traces) and VE-cadherin (red traces) fluorescence after thrombin, histamine or S1P stimulation. Intensity histograms (in arbitrary units, a.u.) were generated for the green (actin) and red (VE-cadherin) fluorescence channel images as function of pixel position (a.u.) along cell cross sections indicated by the white solid lines drawn into the corresponding fluorescence image. Within the intensity plots cell borders are indicated by dashed lines.

FIGURE 2- SOCE inhibitors inhibit thapsigargin-, thrombin-, histamine-, and S1P-activated Ca\(^{2+}\) entry in HDMEC. Fura2 recordings showing changes in intracellular free Ca\(^{2+}\) concentrations represented as Ratio 340/380 (mean ± SD) after stimulation with 2 µM thapsigargin (A, E, I), 100 nM thrombin (B, F, J), 10 µM histamine (C, G, K) and 1 µM S1P (D, H, L). Effect of 2 min pre-incubation with 5 µM Gd\(^{3+}\) (A – D, red traces) on changes in intracellular free Ca\(^{2+}\) mobilization compared to controls (black traces) after stimulation with 2 µM thapsigargin (A), 100 nM thrombin (B), 10 µM histamine (C) and 1 µM S1P (D). In the control black traces, 5 µM Gd\(^{3+}\) was added after Ca\(^{2+}\) entry has reached a plateau. (E – H) Effects of 2 min pre-incubation with 10 µM BTP2 (red traces) on changes in intracellular free Ca\(^{2+}\) mobilization compared to controls (black traces) after stimulation with 2 µM thapsigargin (E), 100 nM thrombin (F), 10 µM histamine (G) and 1 µM S1P (H). In the control black traces,
10 µM BTP2 was added after Ca^{2+} entry has reached a plateau. (I – L) Effects of 2 min pre-incubation with 25 µM 2-APB on Ca^{2+} mobilization induced by thapsigargin (I), thrombin (J), histamine (K) and S1P (L) compared to controls (black traces). In the control black traces and after Ca^{2+} entry has reached a plateau, 5 µM 2-APB was added first to cells followed by 25 µM 2-APB to assess potentiation of Ca^{2+} entry with 5 µM 2-APB and subsequent inhibition with 25 µM 2-APB. In the blue traces, a 2 min pre-incubation with 5 µM 2-APB was performed to reveal potential enhancement of Ca^{2+} entry followed by addition of 25 µM 2-APB after Ca^{2+} entry has reached a plateau. Data are represented as mean ± SD and number of cells per condition are depicted in each figure panel and color-coded for each trace.

**FIGURE 3- Concentration-dependent effect of SOCE inhibitors on HDMEC without GPCR stimulation.** (A – C) Changes in basal electrical resistance over time after addition of different concentrations of Gd^{3+} (A), BTP2 (B) and 2-APB (C) in the absence of stimulation with GPCR agonists are represented. Data are represented as mean ± SD of 4 independent experiments (for Gd^{3+}, except 1 µM Gd^{3+} condition where N = 3) and 3 independent experiments (for all concentrations of BTP2 and 2-APB) per condition. The typical concentrations as used in Fura2 recordings are highlighted in red.

**FIGURE 4- Gd^{3+} effects on barrier function upon stimulation with thrombin, histamine and S1P.** (A – C) Changes in Electrical Resistance after stimulation with thrombin (A), histamine (B), and S1P (C) in the presence of 5 µM (red), 10 µM (magenta) or 50 µM (black) Gd^{3+} compared to vehicle controls (0 µM, blue). Data represent mean ± SD from 3 – 4 independent wells (Gd^{3+}; thrombin: N = 3, histamine: N = 4 and S1P: N = 4, for all Gd^{3+} concentrations. (D – F) Quantification of the maximum change in normalized resistance (Δ Normalized Resistance) upon addition of thrombin (D), histamine (E) and S1P (F) stimulation in the absence or presences of 5 µM, 10 µM or 50 µM Gd^{3+} are shown. Data represented as mean ± SD from 4 – 12 independent experiments as marked in the bar graphs.

**FIGURE 5- BTP2 effects on barrier function in response to thrombin, histamine and S1P.** (A – C) Changes in Electrical Resistance after stimulation with thrombin (A), histamine (B), and S1P (C) in the presence of 1 µM (magenta), 5 µM (black) or 10 µM BTP2 (red) compared to controls (blue). Data represent mean ± SD from 4 independent wells. (D – F) Quantification of the maximum change in normalized resistance (Δ Normalized Resistance) upon thrombin (D), histamine (E) and S1P (F) stimulation in the absence or presence of 1 µM, 5 µM or 10 µM BTP2. Data represented as mean ± SD from 6 – 12 independent experiments as marked in the bar graphs.

**FIGURE 6- 2-APB effects on barrier function in response to thrombin, histamine and S1P.** (A – C) Changes in electrical resistance after stimulation with thrombin (A), histamine (B), and S1P (C) in the presence of 5 µM (magenta), 10 µM (black) or 25 µM (red) 2-APB compared to controls (blue). Data represent mean ± SD from 3 – 6 independent wells. 2-APB; thrombin: N = 4, except for 0 µM 2-APB, where N = 3, histamine: N = 6, S1P: N = 6 for all 2-APB concentrations. (D – F) Quantification of the maximum change in normalized resistance (Δ Normalized Resistance) upon thrombin (D), histamine (E) and S1P (F) stimulation in the absence or presences of 5 µM, 10 µM or 25 µM 2-APB are shown. Data represented as mean ± SD from 6 – 11 independent experiments as marked in the bar graphs.
FIGURE 7- Molecular and functional quantification of STIM1 and Orai1 knockdown efficiency. (A – L) Validation of knockdown efficiency with siSTIM1 #1 and siOrai1 #1: (A, C) Representative Western Blots comparing STIM1 (A) and Orai1 (C) expression 4 days after transfection with siRNA against STIM1 (A) and Orai1 (C), compared side by side to non-targeting control siRNA (siNT). (B, D) Densitometry quantifications of Western Blots from 3 (STIM1) and 4 (Orai1) independent transfections similar to those in A and C. (E, G) Representative Fura2 ratiometric Ca$^{2+}$ imaging traces in response to 2 µM thapsigargin after STIM1 (E) or Orai1 (G) knockdown (red or blue traces) compared to siNT controls (black traces). (F, H) Quantification of the maximal change in thapsigargin-induced Ca$^{2+}$ entry after STIM1 (F) or Orai1 (H) knockdown from 7 – 9 independent experiments per condition. (I, K) Representative ratiometric Ca$^{2+}$ imaging traces in response to 10 µM histamine after STIM1 (I) or Orai1 (K) knockdown (red traces) compared to siNT controls (black traces). (J, L) Quantification of the maximal change in histamine-induced Ca$^{2+}$ entry after STIM1 (J) or Orai1 (L) knockdown from 5 – 7 independent experiments per condition is represented. (M – T) Validation of knockdown efficiency with siSTIM1 #2 and siOrai1 #2: (M, N) Western Blots comparing STIM1 (M) and Orai1 (N) expression after transfection with siSTIM1 #2 (M) and siOrai1 #2 (N) to non-targeting control siRNA (siNT). (O – Q) Representative Fura2 ratiometric Ca$^{2+}$ imaging traces in response to 2 µM thapsigargin (O), 100 nM thrombin (P) or 10 µM histamine (Q) after STIM1 (red traces) or Orai1 (blue traces) knockdown compared to siNT controls (black traces). (R – T) Quantification of the maximal change in thapsigargin- (R), thrombin- (S) or histamine- (T) induced Ca$^{2+}$ entry after STIM1 (red) or Orai1 (blue) knockdown compared to non-targeting control (siNT, black) from 3 independent experiments per condition. Data represent means ± SEM.

FIGURE 8- Dependence of GPCR agonist-mediated changes in HDMEC monolayer resistance on basal resistance values. (A – D) Effect of siRNA treatment on HDMEC monolayer resistance. (E, F) siRNA-untreated control HDMEC cell layers. A, C and E show the resistance increase of HDMEC cell layers over 96 hour period from initial seeding (100,000 cells/cm$^2$) to full maturation. Typically, at full maturation cell monolayers were used in thrombin and histamine stimulation experiments as will be discussed in Figure 10. Traces of basal resistance evolution in siSTIM1 #1-(A, red trace) or siOrai1 #1-(C, blue trace) treated cells are compared to control non-targeting siRNA (siNT, black traces) and shown as average ± SD from an experiment with 8 wells per condition; arrows indicate media changes. (B, D) Quantification of the maximal baseline resistance reached after 4 days post-transfection with siRNA and seeding into ECIS plates are shown as mean ± SE for siSTIM11 (B) or siOrai1 (D) compared to control siNT from 58 – 66 wells/condition as indicated in bar graphs. (E) Growth curve of siRNA-untreated control HDMEC cell layers (average ± SD) of 4 individual cell layers. (F) Quantification of the baseline resistance of control HDMEC cell layers reached after 4 days in culture shown as mean ± SE of 64 individual cell layers. As stated earlier, S1P addition was performed on immature cell layers maintained only 2 days in culture to better resolve S1P-enhancement of barrier function.

FIGURE 9- Effect of STIM1 and Orai1 knockdown on changes in HDMEC cell layer resistance upon stimulation with thrombin, histamine and S1P. (A – C) Changes in resistance of HDMEC monolayers transfected with either siSTIM1 #1 (red traces) or control
siNT (black traces) before and after stimulation (indicated by arrow) with 5 nM thrombin (A), 10 µM histamine (B) and 1 µM S1P (C). (D – F) Changes in resistance of HDMEC monolayers transfected with either siOrai1 #1 (blue traces) or control siNT (black traces) before and after stimulation with 5 nM thrombin (D), 10 µM histamine (E) and 1 µM S1P (F). All traces shown are from representative experiments reflecting averages ± SD of N = 4 – 8 wells per condition as indicated in the respective plots. (G – I) Density plots with statistical analysis on a large set of experiments similar to those in A – F performed on HDMEC monolayers transfected with siSTIM1 #1, siOrai1 #1, siNT and control non-transfected cells and stimulated with thrombin (G), histamine (H) and S1P (I). Data are from 4 – 10 independent HDMEC isolations and reflect 23 – 86 independent wells per experimental condition. Density plots represent the relative distribution of the maximum response intensities to agonist addition. Maximum response intensities were quantified as the difference in resistance between baseline and the maximal response obtained after GPCR stimulation, \( \Delta R \) (Ω). For all agonists responses are shown as positives. Density plots were generated by Kernel density smoothing for histograms (https://stat.ethz.ch/R-manual/R-devel/library/stats/html/density.html). High densities indicate frequent occurrence of these values. In addition to HDMEC populations treated with non-targeting siRNA (siNT), data of siRNA-untreated cells (control) were also included. Vertical lines represent the mean response intensity (G: siNT: 1107 Ω, siOrai1: 951 Ω, siSTIM1: 652 Ω, control: 1040 Ω; H: siNT : 482 Ω, siOrai1: 457 Ω, siSTIM1: 228 Ω, control: 564 Ω; I: siNT: 317 Ω, siOrai1: 229 Ω, siSTIM1: 351 Ω, control: 282 Ω). Data were subjected to ANOVA analysis and significant differences are indicated by asterisks as described in Methods.

(J – O) Changes in resistance of HDMEC monolayers transfected with siSTIM1 #2 (J – L, red traces) or siOrai1 #2 (M – O, blue traces) compared to control siNT (black traces) before and after stimulation (indicated by arrow) with 5 nM thrombin (J, M), 10 µM histamine (K, N) or 1 µM S1P (L, O). All traces shown are from representative experiments reflecting averages ± SD of N = 4 – 8 wells per condition.

**FIGURE 10-** Changes in HDMEC monolayer resistance in response to thrombin in Ca\(^{2+}\) free and Ca\(^{2+}\)-containing HBSS. (A) Time course of changes in HDMEC monolayer electrical normalized resistance upon addition of 100 nM Thrombin in Ca\(^{2+}\) free extracellular HBSS and subsequent restoration of 2 mM Ca\(^{2+}\) to the extracellular solution. Arrow indicates time point of change to Ca\(^{2+}\) free HBSS. (B) Close-up of panel A showing with 3 consecutive arrows the time of switch to Ca\(^{2+}\) free HBSS (–Ca\(^{2+}\)), addition of thrombin at 100 nM in Ca\(^{2+}\) free HBSS and change to HBSS containing 2 mM Ca\(^{2+}\) (+Ca\(^{2+}\)). For this specific experiment, specialized ECIS arrays were used (2W4x1E PC). These arrays had wells with the same dimensions as the chambers used for Ca\(^{2+}\) imaging and ECIS measurements were performed at room temperature. (C) Corresponding Ca\(^{2+}\) imaging trace upon addition of 100 nM Thrombin using the same –Ca\(^{2+}\)/+Ca\(^{2+}\) protocol. (D) Corresponding immunofluorescence staining of VE-cadherin (red), actin (green) and nuclei stain Hoechst (blue) on cells stimulated for 2 min with 100 nM thrombin in the Ca\(^{2+}\) free (upper images) and Ca\(^{2+}\) containing (lower images) HBSS.

**FIGURE 11-** Effect of chelation of intracellular Ca\(^{2+}\) with BAPTA-AM on changes in barrier function in response to thrombin, histamine and S1P. (A – D) Representative recordings of changes in intracellular free Ca\(^{2+}\) in response to stimulation with 2 µM thapsigargin (A), 100 nM thrombin (B), 10 µM histamine (C) and 1 µM S1P (D). Recordings were initiated after 10 minute incubation with vehicle (DMSO control, black trace) or BAPTA-AM at either
1 µM (blue trace; performed only for thapsigargin) or 10 µM (red traces). As 1 µM BAPTA-AM did not fully inhibit Ca^{2+} mobilization in response to thapsigargin, 10 µM BAPTA-AM was used in all subsequent experiments. (E – G) Changes in electrical resistance of confluent HDMEC monolayers after 10 min incubation with 10 µM BAPTA-AM (red traces; BAPTA-AM addition indicated by “B” at the first arrow) compared to vehicle control (DMSO, black traces) and stimulation with 5 nM thrombin (E; second arrow “Thr”), 10 µM histamine (F; second arrow “His”) and 1 µM S1P (G; second arrow “S1P”).
Figure 1

A. Thrombin, 5 nM

B. Histamine, 10 µM

C. S1P, 1 µM

D. Control, Thrombin, Histamine, S1P
Figure 1

E, F: Graphs showing the normalized resistance over time (t) with different treatments:
- E: Thr (Thrombin) treatments at 2 min, 5 min, 10 min, and 30 min.
- F: His (Histamine) treatments at 1 min, 5 min, and 20 min.

G: Micrographs of untreated and treated samples:
- 2 min Thr, 5 min Thr, 10 min Thr, and 30 min Thr.

H: Micrographs of 1 min, 5 min, 20 min Histamine-treated samples.

I: Control untreated samples.

Scale bar: 25 µm.
Figure 1
Figure 2

A. 2 µM Thapsigargin

B. 100 nM Thrombin

C. 10 µM Histamine

D. 1 µM S1P

E. 2 µM Thapsigargin

F. 100 nM Thrombin

G. 10 µM Histamine

H. 1 µM S1P

I. 2 µM Thapsigargin

J. 100 nM Thrombin

K. 10 µM Histamine

L. 1 µM S1P
Figure 3

A) Gd\(^{3+}\) BTP2 2-APB

Normalized Resistance vs. t (min)

B) BTP2

Normalized Resistance vs. t (min)

C) 2-APB

Normalized Resistance vs. t (min)
Figure 5

(A) Thrombin

(B) Histamine

(C) S1P

(D) Δ Normalized Resistance

(E) Δ Normalized Resistance

(F) Δ Normalized Resistance

- **5 µM BTP2**
- **10 µM BTP2**
- **1 µM BTP2**

- **DMSO**

- **Thr**

- **His**

- **BTP2**

- **S1P**

- **N = 6**
- **N = 11**
- **N = 12**

- **N.S.**

- ***** P < 0.001**

- **t (min)**
Figure 6

A) Thrombin

B) Histamine

C) S1P

D) Δ Normalized Resistance

E) Δ Normalized Resistance

F) Δ Normalized Resistance

Data shown as mean ± SEM. N = 9-11. Asterisks indicate significance: * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 7

M

siNT  siSTIM1 #2

GAPDH  STIM1

100 KD  75 KD  37 KD

N

siNT  siOrai1 #2

HSP 70 / HSC 70

37 KD  75 KD

P

100 nM Thrombin

Ratio 340/380

2 mM Ca2+

100 nM Thrombin

Ratio 340/380

2 mM Ca2+

10 μM Histamine

Ratio 340/380

2 mM Ca2+

10 μM Histamine

Ratio 340/380

2 mM Ca2+

N=73

N=25

N=23

N=75

N=32

N=28

N=25

T

Δ Ratio 340/380

siNT  siSTIM1 #2  siOrai1 #2

**

Δ Ratio 340/380

siNT  siSTIM1 #2  siOrai1 #2

***

Δ Ratio 340/380

siNT  siSTIM1 #2  siOrai1 #2

**

Δ Ratio 340/380

siNT  siSTIM1 #2  siOrai1 #2

**

Δ Ratio 340/380

siNT  siSTIM1 #2  siOrai1 #2

**
Figure 8

A) Graph showing baseline resistance (kΩ) over time (h) for siNT and siSTIM1 treatments. The graph depicts an upward trend with arrows indicating significant changes.

B) Bar graph comparing baseline resistance (kΩ) for siNT and siSTIM1 treatments. The graph shows N=64 and N=58 with N.S. indicating no significant difference.

C) Graph showing baseline resistance (kΩ) over time (h) for siNT and siOrai1 treatments. The graph depicts an upward trend with arrows indicating significant changes.

D) Bar graph comparing baseline resistance (kΩ) for siNT and siOrai1 treatments. The graph shows N=66 and N=64 with an asterisk indicating a significant difference.

E) Graph showing baseline resistance (kΩ) over time (h) for siNT and siOrai1 treatments. The graph depicts an upward trend with arrows indicating significant changes.

F) Bar graph showing baseline resistance (kΩ) for control treatment with N=64.
Figure 9

A) Thrombin

B) Histamine

C) S1P

D) S1P

E) S1P

F) S1P

G) Control vs. siNT vs. siOrai1 #1

H) Control vs. siNT vs. siOrai1 #1

I) Control vs. siNT vs. siOrai1 #1
Figure 9

J) Thrombin
K) Histamine
L) S1P

M) siNT and siOrai1 #2
N) siNT and siSTIM1 #2
O) siNT and siSTIM1 #2

Normalized Resistance
Normalized Resistance
Normalized Resistance

N = 8
N = 8
N = 8
N = 8
N = 4
N = 4
N = 4
N = 3

Thrombin Histamine S1P

Downloaded from http://www.jbc.org/ by guest on March 24, 2020
Figure 10

A. Graph showing normalized resistance over time for different conditions.

B. Graph showing the change in normalized resistance upon addition of 100 nM Thrombin with and without 2 mM Ca\(^{2+}\).

C. Graph showing the ratio of 340/380 over time for 100 nM Thrombin with 2 mM Ca\(^{2+}\), with error bars indicating variability among samples (N = 39).

D. Images showing control and Thrombin conditions under HBSS -Ca\(^{2+}\) and HBSS +Ca\(^{2+}\) conditions, illustrating cellular responses.

Legend:
- Control
- Thrombin
- HBSS -Ca\(^{2+}\)
- HBSS +Ca\(^{2+}\)
Calcium Signaling is Dispensable for Receptor-Regulation of Endothelial Barrier Function
Judith A Stolwijk, Xuexin Zhang, Maxime Gueguinou, Wei Zhang, Khalid Matrougui, Christian Renken and Mohamed Trebak

J. Biol. Chem. published online September 13, 2016

Access the most updated version of this article at doi: 10.1074/jbc.M116.756114

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts